Amgen's early view said health care savings from the use of these biologic therapies climbed to $3 billion in the second quarter of 2022, for total of $18 billion over the past 6 years.
Use of biosimilars by US physicians is picking up steam, and the marketplace “is poised to growth” in both approvals and uptake after hiccups caused in part by the pandemic, accordingto a recent industry overview from Amgen.
The 2022 “Trends in Biosimilars Report Preview,” which offers highlights of the biosimilars marketplace ahead of a full report to come this fall, said health care savings from the use of these biologic therapies climbed to $3 billion in the second quarter of 2022, for total of $18 billion over the past 6 years.
Ongoing success of biosimilars is a team effort. “Essential components of provider and patient use of biosimilars include payer coverage as well as addressing the clinical, operational, and economic considerations to help support adoption,” the report notes. With biosimilars poised to remake new therapeutic areas, “provider and pharmacist education will be critical.”
Savings is important, but it’s not the only consideration: payers and physicians alike want to know that manufacturers are producing high-quality drugs and that supply chains are reliable.
US Pace Faster Than Europe at Same Stage
US biosimilar activity hit a peak in 2019 with 10 approvals and 7 launches, but things slowed the next 2 years, in part because regulators’ attention turned toward responding the COVID-19 pandemic. There were 4 US approvals and 2 launches in 2021, and there have been 3 approvals thus far in 2022. However, the Amgen report authors note that there were 97 products in the FDA Biosimilar Development Program in December 2021, up from 77 in March 2019, offering a sign of what’s to come.
The United States did not approve its first biosimilar until 2015, almost a decade after the first product was approved in Europe (2006). Although the European Union (EU) has had quite a head start, the report’s authors note that in year 8, the EU had approved 15 biosimilars, and “by contrast, in the 8 years after the US approved the first biosimilar, there were 36 approvals.”
The authors assert that the rate of biosimilar uptake is increasing and that once these biologics become part of the scene in a therapeutic area, they gain market significant market share. Prior to 2019, the average market share for therapeutic areas with biosimilars was 38%, but today that has climbed to 74%.
Of note, being first matters. “First-to-launch biosimilars tend to capture a greater portion of the segment compared to later entrants,” they write.
Competition With Humira: Waiting on the Game Changer
Thus far, uptake and acceptance of biosimilars has been greater in oncology than in rheutmatology, but that could all change after January 31, 2023. That’s when biosimilars will arrive for Humira (adalimumab), which generated more than $20 billion in sales in 2021.
The prospect of 7 or more adalimumab biosimilar launches in 2023 could lead to reduced spending across multiple autoimmune conditions for which Humira is indicated. “Based on the history of pricing for biosimilar and reference products seen in other areas, the entry of additional biosimilars is expected to lead to greater price declines across all products within the class,” the report states.
What’s next? Amgen’s report predicts that approvals for biosimilars in the US marketplace will move beyond the areas of oncology, autoimmune disease, and endocrinology. A greater focus on education—from providers, to pharmacists, to patients—will lead to new discussions at the pharmacy counter, especially as more interchangeable biosimilars are approved. “These changes are likely to cement the role of biosimilars as viable and integral US treatment options.”
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.